2014-2015 Student Fellowship

2014-2015 Student Fellowship
Petrie-Flom Center, Harvard Law School

Deadline: May 19, 2014

The Center and Student Fellowship.  The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics is an interdisciplinary research program at Harvard Law School dedicated to the scholarly research of important issues at the intersection…

Read More

Academic Fellow W. Nicholson Price II Appointed Asst. Professor at UNH School of Law

Petrie-Flom Center, March 13, 2014

Petrie-Flom Academic Fellow Nicholson Price has been appointed as an Assistant Professor at the University of New Hampshire School of Law, where he will research and teach on intellectual property, innovation policy, and…

Read More

Reforming Brazilian Pharmaceutical Patent Policy:
Lessons from the Past and the Road for the Future

Wednesday, April 23, 2014 12:00 PM
Lectures and Panels
2013-2014
Wasserstein Hall 1010
1585 Massachusetts Ave., Cambridge, MA

In this lecture by Pedro Paranaguá, he will discuss the report issued by the Brazilian House of Representatives in 2013…

Read More

US judge blocks Mass. ban on painkiller:

Boston Globe, April 15, 2014
by Milton J. Valencia

A federal judge struck down the state’s first-of-its-kind emergency ban on Zohydro on Tuesday, saying Massachusetts had no authority to overrule a federal decision to approve the powerful, controversial painkiller.…

Read More

Ebola Drug Could Be Ready For Human Testing Next Year

NPR, April 11, 2014
by Richard Harris

The Ebola outbreak in West Africa is terrifying because there's no drug to treat this often fatal disease. But the disease is so rare, there's no incentive for big pharmaceutical companies to…

Read More

Welcome 2014-2016 Academic Fellow Rachel Sachs!

Petrie-Flom Center, April 17, 2014

The Petrie-Flom Center is pleased to announce the new 2014-2016 Academic Fellow, Rachel Sachs. Rachel earned her J.D. in 2013 magna cum laude from Harvard Law School, where she was the Articles Chair of…

Read More

Supreme Court to Hear Appeal of Generic Drug Case

New York Times, March 31, 2014
by Andrew Pollack

As the world’s largest maker of generic drugs, Teva Pharmaceutical Industries has been critical of brand-name manufacturers that try to block generic versions of their high-priced medicines. But Teva is…

Read More

Make it Work!:

Harvard Law Review 128, 2014
by I. Glenn Cohen (Faculty Co-Director)

This short essay is part of a Harvard Law Review Symposium honoring Justice Breyer on his 20th Year on The Supreme Court. It examines Breyer's opinions and impact on the…

Read More

The “Problem” with the European Problem/Solution Approach to Inventive Step

Los Angeles Intellectual Property Law Association, Wegner's Writings, February 24, 2014
by Harold C. Wegner, reviewing Timo Minssen (Petrie-Flom Visiting Scholar)

From the review: Patent applicants seeking to gain global patent protection beyond their home country borders need a better comparative knowledge of key elements of the patent laws of the several…

Read More

Patents Without Patents:
Regulatory Incentives for Innovation in the Drug Industry

Wednesday, February 19, 2014 12:00 PM
Lectures and Panels
2013-2014
Wasserstein Hall 1015
1585 Massachusetts Ave., Cambridge, MA

Watch Event Recordings

In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs.  But patents aren’t the whole…

Read More

Novartis puts pressure on India over patent abuse

Financial Times, February 16, 2014
by Andrew Ward and Amy Kazmin

Novartis has urged US and European governments to “apply pressure” on India to respect intellectual property and warned New Delhi that its stance on patents is deterring investment. Joe Jimenez,…

Read More

Patent Trolling:

by Robin Feldman and W. Nicholson Price II (Petrie-Flom Academic Fellow)

Abstract: Patent trolls — also known variously as non-practicing entities, patent assertion entities, and patent monetizers — are a top priority on legislative and regulatory reform agendas. In the modern…

Read More

Legal Aspects of Biobanking as Key Issues for Personalized Medicine & Translational Exploitation

by Timo Minssen (Petrie-Flom Visiting Scholar) and Jens Schovsbo

Abstract: This perspective-article provides an overview on selected legal aspects of biobanking. It discusses these issues with a focus on public biobanks in a university setting and the specific challenges posed…

Read More

NEW BOOK: Science and Technology in International Economic Law:

Routledge, 2014
by Bryan Mercurio and Kuei-Jung Ni (Petrie-Flom Visiting Scholar), editors

Science and technology plays an increasingly important role in the continued development of international economic law. This book brings together well-known and rising scholars to explore the status and interaction…

Read More

Do Fixed Patent Terms Distort Innovation?:

Public Health Law & Policy e-Journal 5, no. 64, December 4, 2013
by Eric B. Budish, Benjamin N. Roin, and Heidi Williams

Abstract: Patents award innovators a fixed period of market exclusivity, e.g., 20 years in the United States. Yet, since in many industries firms file patents at the time of discovery ("invention")…

Read More

Genes without Patents

Harvard Gazette, November 14, 2013
by Alvin Powell, featuring I. Glenn Cohen

As Supreme Court Justice Elena Kagan questioned Myriad Genetics’ attorney about patenting genes, Chris Hansen rejoiced. The attorney said that yes, genes should be patentable. But it was only under…

Read More

GMO food fight brings in big bucks in Washington state

Al Jazeera America, October 28, 2013
by Michael Ames

A bitter fight in Washington state over whether to label foods with ingredients that have been genetically modified has attracted tens of millions of dollars in spending, more than $27…

Read More

Pharma manufacturing woes dog industry

Chemistry World, October 23, 2013
by Sarah Moulton, quoting W. Nicholson Price II

[...] While many of these problems arise from quality control failures, according to Nicholson Price from Harvard Law School’s Petrie-Flom centre for health law policy, biotechnology and bioethics, this is not the…

Read More

Open Access Week 2013:
Promoting Access to Federally Funded Research

Monday, October 21, 2013 12:00 PM
Lectures and Panels
2013-2014
Wasserstein Hall, Room 4063
1585 Massachusetts Ave., Cambridge, MA

2013 has seen many milestones towards improving access to biomedical research. In February, President Obama issued an Executive Order requiring…

Read More

Chris Hansen on “Dis-Owning Nature: The BRCA Gene Patents and the Supreme Court”

Program on Science, Technology, & Society at HKS, November 12, 2013
by Featuring I. Glenn Cohen as a discussant

ABOUT THE SPEAKER Chris Hansen joined the ACLU in 1973. He spent 10 years at the NYCLU specializing in complex litigation seeking reform of the mental retardation and mental health…

Read More

Praise for “Making Do in Making Drugs” by W. Nicholson Price II

Written Description: Patent & IP Blog, Reviewing Recent Scholarship on Patent Law, IP Theory, and Innovation, September 28, 2013
by Camilla Alexandra Hrdy

"'M&M chocolate candies are made with a precision far beyond the capabilities of many drug manufacturers.' This is the intriguing opening to a thorough critique of innovation in pharmaceutical manufacturing by Nicholson…

Read More

Making Do in Making Drugs:

Boston College Law Review, forthcoming
by W. Nicholson Price II

Abstract:   Drug recalls, contamination events, and shortages are on the rise, but drug companies still rely on decades-old manufacturing plants and processes. Contrary to widespread perceptions, drug manufacturing is…

Read More

Compulsory License and Access to Medicine:
The Indian Experience to Date

Monday, September 16, 2013 12:00 PM
Lectures and Panels
2013-2014
Wasserstein Hall, B015
1585 Massachusetts Ave., Cambridge, MA

A lecture by V. Lakshmikumaran. Presented by the Program on the Legal Profession at Harvard Law School, in cooperation with…

Read More

Association for Molecular Pathology v. Myriad Genetics

by Oyez Project

In June 2013, the Supreme Court held that naturally occurring gene sequences and their naturally occurring derivatives are not patent eligible.  This link includes a brief summary of the case,…

Read More

Myriad Gene Patent Litigation

Genomics Law Report

This link provides several viewpoints regarding the Myriad Genetics case.

Read More

7 Takeaways from Supreme Court’s Gene Patent Decision

Daily News, National Geographic

Shortly after the Supreme Court ruling in Myriad, this article summarizes the implications of the decision and its influence on the biotech industry.

Read More

Gene Patents

The Hastings Center Bioethics Briefing Book
by Robert Cook-Deegan

Intended for a lay audience, this chapter outlines key issues in the debate about gene patents and summarizes historical developments in the field.

Read More

Patents in Genomics and Human Genetics

Annual Review of Genomics and Human Genetics
by Robert Cook-Deegan and Christopher Heaney

This article provides a more detailed and scholarly overview of the issues.

Read More

Issues and Case Studies in Clinical Trial Data Sharing:
What Have We Learned?

Friday, May 17, 2013
Conferences
2012-2013
Wasserstein Hall, Milstein East, Harvard Law School
1585 Massachusetts Ave., Cambridge, MA
Watch Event Recordings

Objectives: To convene key global stakeholders on a neutral platform to review evidence from recent case studies in clinical trial…

Read More

Debunking the Myth that Whole-Genome Sequencing Infringes Thousands of Gene Patents

Nature Biotechnology
by Christopher M. Holman

This article addresses misconceptions regarding gene patents and whole-genome sequencing.

Read More

Mayo Collaborative Services v. Prometheus Laboratories

by Oyez Project

In this case, the Supreme Court held that the processes involved in a test for proper dosages of drug treatments are unpatentable laws of nature.

Read More

Personalized Medicine Patenting

Wednesday, March 06, 2013
Lectures and Panels
2012-2013
Austin Hall 111, Harvard Law School
Watch Event Recordings

Pharmaceutical researchers pursue medical treatment and diagnostic methods to target diseases specific to certain demographic groups. Such pursuit is often motivated…

Read More

Mayo v. Prometheus: Implications for Patents, Biotechnology, and Personalized Medicine

by Congressional Research Service

This article discusses the implications of the Mayo v. Prometheus decision, including its potential impact on gene patents.  It also suggests possible routes that Congress can take on the issue…

Read More

Patent Policy and Innovation

Friday, April 23, 2010
2009-2010

This panel focused on how patent law affects various industries differently. The pharmaceutical and high-tech industries offer perhaps the most vivid…

Read More

Developments and Implications of New Legislation on Follow-on Biologics

Wednesday, January 06, 2010
Lectures and Panels
2009-2010

This panel examined current legislative debates concerning the development of regulatory approval processes for follow-on biologics, or large molecule drugs that…

Read More

Medical Prize Funds:
An Alternative Reward Mechanism for Medical Innovation

Thursday, November 05, 2009
Lectures and Panels
2009-2010

Patenting and other rewards that rely on protected markets to encourage research investment in medical technology do not always provide the…

Read More